Hepanova, Inc.

GAITHERSBURG, MD · Biotech · Private

IKK inhibitor therapeutics for chronic liver disease and inflammation

Claim this profile

Follows are private to you and power your alerts

Updated · hepanova.com

Sector
Biotech
Headquarters
GAITHERSBURG, MD
Latest Form D
$450K, Jan 2021
Total capital
$1.4M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$1.4M
2 Form D · last Jan 2021
70 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
2
4 pending · first 2021
Rank in peer group#397 of 1449

Capital timeline

201920202021FEDERAL ↑EQUITY ↓Cumulative $1.4M1st Form D$1M2nd Form D$450K
201920202021FEDERAL ↑EQUITY ↓Cumulative $1.4M1st Form D$1M2nd Form D$450K

Latest events

  • Private capital raisedForm D · SEC · 2nd filing$450K
  • Private capital raisedForm D · SEC · 1st filing$1M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#397 · top 27%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • KE Q. LIResearcherDirectorLinked by 2 patents
  • Belle X WangExecutive Officer, DirectorNamed in SEC Form D filings
  • FRANK Q. LIExecutive Officer, DirectorNamed in SEC Form D filings
  • QISHENG LIExecutive Officer, DirectorNamed in SEC Form D filings
  • Yuanzhang WangExecutive Officer, DirectorNamed in SEC Form D filings

What it has protected

USPTO · 2 granted of 6
Show all 6 patent records
  • Amino-aryl-benzamide Compounds And Methods Of Use ThereofJul 3, 2025 · Application 18794419Pending
  • Amino-aryl-benzamide Compounds And Methods Of Use ThereofAug 6, 2024 · US 12,053,443Granted
  • Amino-aryl-benzamide Compounds And Methods Of Use ThereofMay 11, 2021 · US 11,000,491Granted
  • Amino-aryl-benzamide Compounds And Methods Of Use ThereofApplication PCTUS2018031072Pending
  • Amino-diaryl-benzamide Compounds And Methods Of Use ThereofApplication 62539036Pending
  • Method Of Treating Nonalcoholic Fatty Liver Disease (nafld) And Nonalcoholic Steatohepatitis (nash)Application 62502385Pending
  • Enkefalos Biosciences, Inc.Similar federal contract value in Biotech · null in contracts
  • Accuitis Inc.Similar federal contract value in Biotech · null in contracts
  • CALOSYN PHARMA, INC.Similar federal contract value in Biotech · null in contracts
  • Telos Biotech Inc.Similar federal contract value in Biotech · null in contracts
  • Koniku Inc.Similar federal contract value in Biotech · null in contracts
  • Bakhu Holdings, Corp.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .